Federal Register of Legislation - Australian Government

Primary content

PB 34 of 2021 Determinations/Health as made
This instrument amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015) to determine the originator brand of a pharmaceutical item for five drugs new to the Pharmaceutical Benefits Scheme (PBS) F2 formulary on 1 April 2021.
Administered by: Health
Registered 31 Mar 2021
Table of contents.

Commonwealth Coat of Arms of Australia

 

PB 34 of 2021

 

National Health (Originator Brand) Amendment Determination 2021 (No. 2)

 I, Thea Connolly, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health and Aged Care, make the following Determination.

Dated               31 March 2021                       

THEA CONNOLLY

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

 

 

 

 

 

 

 

 

 

 

 

Contents

1  Name........................................................................................................................................ 1

2  Commencement........................................................................................................................ 1

3  Authority.................................................................................................................................. 1

4  Schedules................................................................................................................................. 1

Schedule 1—Amendments                                                                                           2

National Health (Originator Brand) Determination 2015 (PB 100 of 2015)                            2

 

 


1  Name

                   This instrument is the National Health (Originator Brand) Amendment Determination 2021 (No. 2).

                   This instrument may also be cited as PB 34 of 2021.

2  Commencement

             (1)  Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1.  The whole of this instrument

 1 April 2021

 

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

             (2)  Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

                   This instrument is made under subsection 99ADB(6B) of the National Health Act 1953

4  Schedules

                   Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.


Schedule 1Amendments

National Health (Originator Brand) Determination 2015 (PB 100 of 2015)

1  Schedule 1, (after table item 2)

Insert:

2A

Adalimumab

Humira

 

 

2  Schedule 1, (after table item 29)

Insert:

29A

Cabazitaxel

Jevtana

 

 

3  Schedule 1, (after table item 41B)

Insert:

41C

Cinacalcet

Pharmacor Cinacalcet

 

 

4  Schedule 1, (after table item 76)

Insert:

76A

Erlotinib

Tarceva

 

 

5  Schedule 1, (after table item 96A)

Repeal the item:

96B

Gefitinib

Iressa

 

 

 

Substitute:

96B

Ganirelix

Orgalutran

 

 

96C

Gefitinib

Iressa